{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:39Z","timestamp":1793121339190,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,12]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is known to develop during these treatments. Among these mechanisms, histological transformation is seldom encountered. Although platinum based chemotherapy has been reported to be effective in the treatment of patients with small cell lung cancer transformation, there is a lack of information on the treatment of patients with squamous cell carcinoma (SQ) transformation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient Concerns and Diagnosis:<\/jats:title>\n            <jats:p>An 80-year-old nonsmoking woman was referred to our hospital because of an abnormal shadow on her chest radiograph. Diagnostic bronchoscopy was performed and pathological examination revealed adenocarcinoma. Mutation analysis of the EGFR gene revealed deletion of E746-A750 in exon 19. She refused both surgical treatment and radiation therapy, and preferred periodic radiologic follow-up. Unfortunately, approximately a year and a half after the initial diagnosis, the primary lesion enlarged, and many pleural nodules were newly detected (clinically T4N2M1a, stage IVA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and Outcomes:<\/jats:title>\n            <jats:p>Based on EGFR mutation analysis, a reduced dose of daily erlotinib was prescribed, which achieved a partial response and 34 months of progression-free survival (PFS). A repeated biopsy with an endobronchial cryoprobe was performed on the enlarged primary lesion. Pathological examination revealed SQ harboring an identical EGFR mutation with a secondary EGFR T790M mutation. Osimertinib 80\u2009mg once a day was started as second line therapy, which resulted in 8 months of PFS and 15 months of survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lesson:<\/jats:title>\n            <jats:p>The literature review and our report suggest that osimertinib is a promising treatment for NSCLC regardless of histology if T790M is present as an acquired mutation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029682","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:08:38Z","timestamp":1660313318000},"page":"e29682","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-1119","authenticated-orcid":false,"given":"Yusaku","family":"Kusaba","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-646X","authenticated-orcid":false,"given":"Yuichiro","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Naka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1759-7714.13035","article-title":"Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure.","volume":"10","author":"Zhou","year":"2019","journal-title":"Thorac Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC.","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1186\/s12885-020-07424-w","article-title":"Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.","volume":"20","author":"Takeda","year":"2020","journal-title":"BMC Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"75ra","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/cts.12796","article-title":"Phase I\/II Study of erlotinib to determine the optimal dose in patients with non-small cell lung cancer harboring only EGFR mutations.","volume":"13","author":"Takeda","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcph.1042","article-title":"Pharmacokinetics of osimertinib in chinese patients with advanced NSCLC: a phase 1 study.","volume":"58","author":"Zhao","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10147-017-1211-1","article-title":"Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.","volume":"23","author":"Shao","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2018.11.016","article-title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.","volume":"127","author":"Roca","year":"2019","journal-title":"Lung Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.6004\/jnccn.2013.0126","article-title":"EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.","volume":"11","author":"Scher","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.athoracsur.2014.02.075","article-title":"Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.","volume":"99","author":"Hsieh","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/JTO.0000000000000571","article-title":"Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition.","volume":"10","author":"Levin","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jclinpath-2015-202866","article-title":"Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.","volume":"68","author":"Kuiper","year":"2015","journal-title":"J Clin Pathol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.jtho.2015.12.096","article-title":"Squamous Cell Carcinoma \u201cTransformation\u201d Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.","volume":"11","author":"Jukna","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdv495","article-title":"Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.","volume":"27","author":"Haratani","year":"2016","journal-title":"Ann Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.jtho.2017.06.071","article-title":"Osimertinib for epidermal growth factor receptor mutation-positive lung adenocarcinoma that transformed to T790M-positive squamous cell carcinoma.","volume":"12","author":"Okabe","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.11.012","article-title":"Synchronous occurrence of squamous-cell carcinoma \u201ctransformation\u201d and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.","volume":"103","author":"Longo","year":"2017","journal-title":"Lung Cancer"},{"key":"R19-20250504","first-page":"5947","article-title":"Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.","volume":"14","author":"Bruno","year":"2017","journal-title":"Oncol Lett"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4132\/jptm.2016.10.18","article-title":"Metastatic squamous cell carcinoma from lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor therapy.","volume":"51","author":"Park","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.cllc.2017.10.005","article-title":"Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: a case report and literature review.","volume":"19","author":"Izumi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.jtho.2018.07.100","article-title":"Osimertinib for secondary T790M-mutation-positive squamous cell carcinoma transformation after afatinib failure.","volume":"13","author":"Kong","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"E526","DOI":"10.21037\/jtd.2018.06.83","article-title":"Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.","volume":"10","author":"Shinohara","year":"2018","journal-title":"J Thorac Dis"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e0650","DOI":"10.1097\/MD.0000000000010650","article-title":"Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.","volume":"97","author":"Yao","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.2169\/internalmedicine.0999-18","article-title":"An EGFR-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib.","volume":"57","author":"Sato","year":"2018","journal-title":"Intern Med"},{"key":"R26-20250504","first-page":"127","article-title":"Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.","volume":"11","author":"Yamaguchi","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jfma.2019.12.017","article-title":"Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.","volume":"119","author":"Chiang","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e00521","DOI":"10.1002\/rcr2.521","article-title":"Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases.","volume":"8","author":"Uruga","year":"2020","journal-title":"Respirol Case Rep"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/mco.2020.2152","article-title":"Transformation from adenocarcinoma to squamous cell carcinoma associated with long-term administration of EGFR-TKIs.","volume":"13","author":"Haruki","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2169\/internalmedicine.3542-19","article-title":"Combined small and squamous transformation in EGFR-mutated lung adenocarcinoma.","volume":"59","author":"Hakozaki","year":"2020","journal-title":"Intern Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/j.cllc.2020.06.026","article-title":"Transformations first into squamous-cell carcinoma and later into sarcomatoid carcinoma after acquired resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma: case report.","volume":"22","author":"Lee","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes.","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:01:15Z","timestamp":1746334875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":34,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029682","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}